LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway

Maolin Mu1,2 · Wanxiang Niu1,2 · Xiaoming Zhang1,2 · Shanshan Hu1,2,3 · Chaoshi Niu1,2,3

Received: 20 March 2020 / Revised: 5 August 2020 / Accepted: 10 September 2020 / Published online: 25 September 2020
© The Author(s) 2020. This article is published with open access

Abstract
Glioma is the most common malignant tumor in the central nervous system. Altered long noncoding RNAs (lncRNAs) are playing regulatory roles in physiological and pathogenic processes in cancer. Here, we uncovered a differentially expressed lncRNA called brain cytoplasmic RNA 1 (BCYRN1), and elucidated its function and molecular mechanism in the progression and development of glioma. Three fresh tumor tissues from glioma patients and three normal brain tissues from craniocerebral trauma patients were prepared for high-throughput RNA sequencing. Differential RNA transcripts and BCYRN1 were identified by RT-qPCR in glioma samples and controls. CCK-8, colony formation assays, flow cytometry, TUNEL assays, cell migration assays, wound-healing assays, and xenograft model were established to investigate the biological function of BCYRN1 both in vitro and in vivo. Various bioinformatics analysis, dual-luciferase reporter assays, biotinylated RNA pulldown assays, and rescue experiments were conducted to reveal the underlying mechanisms of competitive endogenous RNAs (ceRNAs). 183 lncRNAs were identified with significant dysregulation in glioma and randomly selected differential RNAs were further confirmed by RT-qPCR. Among them, BCYRN1 was the most downregulated lncRNA, and its low expression positively correlated with glioma progression. Functionally, BCYRN1 overexpression inhibited cell proliferation, migration in glioma cell lines, whereas BCYRN1 depletion resulted in the opposite way. MiR-619-5p was further confirmed as the direct target of BCYRN1. Mechanistically, miR-619-5p specifically targeted the CUE domain containing protein 2 (CUEDC2), and BCYRN1/miR-619-5p suppressed glioma tumorigenesis by inactivating PTEN/AKT/p21 pathway in a CUEDC2-dependent manner. Overall, our data presented that the reduced expression of BCYRN1 was associated with poor patient outcome in glioma. BCYRN1 functioned as a ceRNA to inhibit glioma progression by sponging miR-619-5p to regulate CUEDC2 expression and PTEN/AKT/p21 pathway. Our results indicated that BCYRN1 exerted tumor suppressor potential and might be a candidate in the diagnosis and treatment of glioma.

Introduction
Glioma is the most prevalent and malignant primary intracranial tumor. Glioblastoma multiforme (GBM) is one of the most lethal forms of human cancers with average survival rate of 12–15 months [1, 2]. With the aggravation of population aging, glioma is becoming a more and more serious threat to human health. Therefore, early diagnosis and treatment is a crucial medical problem. Due to the invasiveness nature of glioma, it is very difficult to be completely removed in the surgery [3]. What’s worse is this tumor resistant to radiation therapy and chemotherapy and easy to recurrence [1, 2]. Thus, molecular diagnosis, especially various biomarkers are necessary to be investigated during glioma occurrence and progression.

Dysregulated transcripts including mRNAs, microRNAs (miRNAs), lncRNAs, and circular RNAs (circRNAs) can
be a primary feature in human cancers [4–13]. With the rapid development of high-throughput RNA sequencing and the wide application of bioinformatics, lncRNAs, as one subset of ncRNAs with the length >200 nucleotides, were identified to participate in diverse biological processes in cancer [7–9]. There are multiple kinds of mechanisms in cell development and disease for lncRNAs. For instance, Evx1as, a nuclear antisense lncRNA, was reported to regulate gene transcription in cis [14]. Xist is one of the most famous lncRNAs, which recruits blocking factors leading to X inactivation [15]. Metastasis associated lung adenocarcinoma transcript 1 (Malat1) is thought to form molecular scaffolds for ribonucleoprotein complexes, which was also reported to serve as a transcriptional regulator for numerous genes, including some genes involved in cancer metastasis, cell migration, and cell cycle [16, 17]. 5S-OT is a lncRNA overlapped with 5S rRNA, which interacts with U2AF65 to modulate alternative splicing through RNA: RNA pairing [10]. Some lncRNAs act as the miRNA precursors to give rise to miRNAs to target genes [18]. Growing evidences have implicated that a number of lncRNAs functioned as ceRNAs to affect the occurrence and development of cancers. Taken as an example, H19, a well-known lncRNA, was highly regulated in glioma. H19 induced endothelial cell proliferation, migration, and tube formation in vitro, which were proved to exert an H19-mir-29a-VASH2 axis to regulate the tumorigenesis [19]. In glioma, a number of lncRNAs have been found to be significantly dysregulated, such as HOTAIR, TUG1, and ECONEXIN [20–24]. Nevertheless, the various functions and multiple mechanisms of lncRNAs in glioma have not been explored comprehensively.

MiRNAs are endogenously expressed small noncoding RNAs with a length of ~20–22 nucleotides, which play central roles in the ceRNA hypothesis [25]. MiRNAs are highly conserved across species, and regulate gene expression by binding to the 3′-untranslated region (3′-UTR) of target mRNAs. More and more miRNAs were demonstrated to play important roles in glioma [26–28].

In this study, we investigated the expression profiling of lncRNAs and identified a most downregulated lncRNA called BCYRN1 in glioma from RNA-seq. Lower BCYRN1 expression was related to poor prognosis of glioma patients. Furthermore, we found that BCYRN1 affected the proliferation, apoptosis, migration, invasion abilities in vitro and inhibited the tumor formation in vivo. In addition, our study revealed a mechanism that BCYRN1 competitively bind miR-619-5p to regulate glioma progression through inactivating the CUEDC2/PTEN/AKT/p21 pathway. Our results indicate that BCYRN1 exerts as a tumor suppressor in glioma and has the potential to be the promising therapeutic target for glioma diagnosis, therapy, and prognosis.

Results

Transcriptome profiling in glioma and characterization of IncRNA BCYRN1

In order to obtain a comprehensive and profound view of lncRNA transcripts in glioma, we performed high-throughput RNA sequencing using three tissue samples from glioma patients (diagnosed by enhanced MRI and pathology) and three normal brain tissues from craniocerebral trauma patients (Fig. s1a, b). To ensure the authenticity and validity of RNA-seq data, we performed the Pearson’s correlation coefficient analysis of all transcripts between each sample (Fig. 1a). Tumor tissues or control tissues themselves demonstrated the higher correlation compared to each other (Fig. 1a). Notably, we found the expression levels of some previously reported mRNAs and lncRNAs were significantly dysregulated in our data (Table S1). Circos plots globally and genome-widely displayed 1344 kinds of detected lncRNAs in glioma tissues and controls (Fig. 1b). Volcano plots were performed for all expressed lncRNAs (Fig. 1c). There were 183 lncRNAs showed significantly dysregulated in glioma, in which 121 were downregulated while 62 were upregulated (Fig. 1c, Fig. s1c). Hierarchical cluster analysis was also constructed to reveal the differential expression of lncRNAs in glioma tissues and controls (Fig. s1c). To validate the results, 6 lncRNAs were randomly selected for RT-qPCR analysis. THBS3, ATP6VOE, and LINC01235 were significantly upregulated while USP32P2, RTN3, and LINC00294 were markedly downregulated in glioma compared to controls (Fig. s1d). All these validations were consistent with the RNA-seq data. BCYRN1, as the most downregulated IncRNA in glioma, was chosen for further studies.

Next, we confirmed the downregulated expression of BCYRN1 in 22 normal tissues and 111 glioma tissues (46 Grade I and II, 65 Grade III and IV) by RT-qPCR, and found that the expression of BCYRN1 was significantly lower in glioma tissue, especially reduced with advanced glioma grade (Fig. 1d, Table 1). In addition, we assessed the correlation between BCYRN1 expression and prognosis of glioma patients. Kaplan–Meier analysis of TCGA database demonstrated that patients with lower BCYRN1 expression were more likely to be poor overall survivals (Fig. 1e). Taken together, these data suggested that BCYRN1 down-regulation was common in glioma tissues and was correlated with poor prognosis.

BCYRN1 inhibits glioma progression in vitro and in vivo

To identify cellular localization of BCYRN1, RT-qPCR analysis of nuclear and cytoplasmic RNAs was carried out to show
that BCYRN1 was preferentially located in the cytoplasm (Fig. 1f), consistent with the subcellular fractionation in other cancer types [29–31]. Furthermore, five kinds of glioma cell lines were tested the endogenous expression level of BCYRN1. Based on the results, T98G and U251 were selected for the loss-of-function and gain-of-function assays in vitro (Fig. 1g).
To explore the functional roles of BCYRN1, we over-expressed the full length in U251 and T98G cells (Fig. 2a, Fig. s2a). Two short interfering RNAs against different region of BCYRN1 were performed, which effectively knockdown BCYRN1 expression level in T98G and U251 cells (Fig. 2b, Fig. s2b). CCK-8 and colony formation assay revealed that overexpression of BCYRN1 inhibited cell growth and colony formation (Fig. 2c, e, Fig. s2c, e). On the other hand, flow cytometry and TUNEL assay demonstrated overexpression of BCYRN1 induced cell apoptosis (Fig. 2g, i, Fig. s2g, i). In addition, transwell and wound-healing assay displayed that upregulation of BCYRN1 significantly reduced cell migratory capacity (Fig. 2k, m, Fig. s2k, m). In contrast to overexpression, ablation of BCYRN1 promoted cell growth, colony formation, migration, and repressed cell apoptosis in U251 and T98G cells (Fig. 2d, f, h, j, l, n, Fig. s2d, f, h, j, l, n).

In order to investigate regulatory roles of BCYRN1 on tumor growth in vivo, we established U251 stable cell line with lentivirus-BCYRN1 to overexpress BCYRN1. The procedure of in vivo tumor xenograft assay was showed (Fig. 3a). Overexpression efficiency of BCYRN1 was revealed by RT-qPCR assays (Fig. 3b). We observed that tumor size and weights were reduced in the LV-BCYRN1 group compared with those in the LV-vector group (Fig. 3c–h). IHC staining revealed that Ki-67 expression was downregulation upon BCYRN1 overexpression in dissected tumors (Fig. 3i, j). Collectively, these results in vitro and in vivo strongly suggested that BCYRN1 was a potential tumor suppressor in glioma.

**BCYRN1 acts as a ceRNA for miR-619-5p in glioma**

As shown in Fig. 1f, BCYRN1 was preferentially located in the cytoplasm. It has been shown that cytoplasmic lncRNAs can act as miRNAs sponge to regulate downstream targets [32–34]. In order to explore whether BCYRN1 might also function as the ceRNA mechanism, we searched candidate miRNAs by miRanda prediction. We observed that multiple miRNAs were able to align to lncRNA BCYRN1 and blast scores of miR-619-5p was the highest (Fig. 4a). miR-619-5p showed a severe overexpression in 30 glioma samples compare to control samples (Fig. s3a, Table S2). MiR-619-5p expression was the highest in U251 and was the lowest in T98G, which was inverse to BCYRN1 in the two cell lines (Fig. s3b). Furthermore, the miR-619-5p level was negatively correlated with the lncRNA BCYRN1 level in the glioma tissues (Fig. 4b). Overexpression of BCYRN1 led to the significant downregulation of miR-619-5p, whereas its silencing resulted in the upregulation of miR-619-5p (Fig. 4c, d).AGO2 immunoprecipitation (IP) was performed to determine whether BCYRN1 served as a component for AGO2 and miR-619-5p complex. It turned out BCYRN1 was enriched in AGO2 IP of miR-619-5p.
transfected cells (Fig. 4e, f). To verify that BCYRN1 could bind to miR-619-5p, luciferase reporters containing wild-type (BCYRN1-WT) and mutated miR-619-5p binding sites (BCYRN1-MUT) were constructed. We observed that luciferase activity of BCYRN1-WT was significantly reduced after co-transfection of miR-619-5p mimic, but
BCYRN1 inhibits glioma progression by targeting miR-619-5p/CUEDC2

MiRNAs exert various biological functions by targeting mRNAs. To explore the mechanism of BCYRN1/miR-619-5p in glioma progression, we performed comprehensive bioinformatic analysis using four datasets and found that 44 mRNAs might be the potential targets of miR-619-5p including CUEDC2 (Fig. 5a), which was reported to be a tumor suppressor in glioma [35]. CUEDC2 showed an obvious downregulation in 30 glioma samples compared to control samples (Fig. s5a, Table S2). Kaplan–Meier analysis of TCGA database demonstrated that patients with lower CUEDC2 expression were more likely to be poor overall survivals (Fig. s5b).

Importantly, the miR-619-5p level was inversely correlated with the CUEDC2 level in the glioma tissues (Fig. 5b). Furthermore, both the mRNA and protein levels of CUEDC2 were decreased or increased after treated with miR-619-5p mimic or inhibitor, respectively (Fig. 5c). Then we used TargetScan database to predict the binding site of miR-619-5p on CUEDC2 3′-UTR region (Fig. 5d). Luciferase assays were performed to verify a direct interaction between miR-619-5p and CUEDC2. CUEDC2 3′-UTR sequence containing the seed region of miR-619-5p (CUEDC2-WT) and mutated miR-619-5p binding sites (CUEDC2-MUT) were constructed and transfected into 293T cell line. The results showed that luciferase activity of CUEDC2-WT was significantly reduced after co-transfection of miR-619-5p mimic, but luciferase activity of CUEDC2-MUT did not change (Fig. 5d). Upregulation of CUEDC2 could partially rescue the promotive effects of miR-619-5p on cell growth and migration (Fig. 5e–g), while inhibition of CUEDC2 could partially rescue the reductive effects of miR-619-5p on cell growth and migration in glioma (Fig. s5c-e). These findings indicated that CUEDC2 was the target of miR-619-5p.

We found that the CUEDC2 level was positively correlated with the BCYRN1 level in the glioma tissues (Fig. 5h). To verify whether the CUEDC2 gene was modulated by BCYRN1, overexpression and knockdown of BCYRN1 were performed. The results showed that both the mRNA and protein levels of CUEDC2 were decreased or increased upon BCYRN1 overexpression or knockdown, respectively (Fig. 5i–k). Uptregulation of BCYRN1 could rescue the inhibitory effect of miR-619-5p mimic on CUEDC2 expression, while knockdown of BCYRN1 could partially rescue the induction of miR-619-5p inhibitor on CUEDC2 expression both in mRNA and protein level (Fig. 5l–n). Taken together, these data provided evidences that inhibition glioma progression of BCYRN1 was primarily dependent on the miR-619-5p/ CUEDC2 axis.

BCYRN1/miR-619-5p/CUEDC2 axis negatively regulates glioma via PTEN/AKT/p21 pathway

Gene Ontology (GO) biological process enrichment analyses of the 44 mRNAs in the network demonstrated the functional associations with several important pathways, including biological processes such as response to stimulus, cell communication, signal transduction, especially PI3K/Akt signaling pathway (Fig. 6a). It is well
Fig. 3 BCYRN1 inhibits glioma tumor formation in vivo. a Illustration of the tumor transplantation timelines when treated with BCYRN1 overexpression lentivirus. The divergent arrows indicate the different stages. b Expression level of BCYRN1 in U251 cells after transduction with overexpression lentivirus. c The tumor sizes were measured. d Bioluminescence imaging of xenograft tumors in mice was shown. e Stable U251 cells (1 × 10⁷ per mouse, n = 5 each group) were subcutaneously injected into BALB/c nude mice (two groups) to establish subcutaneous xenograft tumors. f The dissected tumors were photographed. g, h The tumor volumes and weights were measured. i, j IHC staining revealed the expression of Ki67, CUEDC2, PTEN, P-AKT, P21 when treated with BCYRN1 overexpression lentivirus. Scale bars, 50 μm. Error bars, S.E.M. from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 by two-tailed Student’s t test.
established that PI3K/Akt signaling played an important regulatory role in glioma, and we examined the pathway-related proteins by western blot. Knockdown of BCYRN1 showed activation of AKT signaling, increased expression of Phosphorylated-AKT (P-AKT) protein, decreased expression of PTEN and P21 (Fig. 6b).
LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2.

In addition, overexpression of BCYRN1 in vivo led to decrease of P-AKT and increase of CUEDC2, PTEN, and P21(Fig. 3i, j). As expected, overexpression of miR-619-5p, as well as knockdown CUEDC2, also activated AKT to GAPDH. The ΔCt values (normalized to GAPDH) were subjected to Pearson correlation analysis (R² = 0.8526, P < 0.0001). e Expression level of miR-619-5p in U251 cells after transfection with overexpression plasmids of BCYRN1. d Expression level of miR-619-5p in T98G cells treated with siRNAs of BCYRN1. e f RIP was performed using AGO2 antibody in T98G and U251 cell lines transfected with miR-619-5p mimics or mimics NC, then the enrichment of BCYRN1 was detected. g The binding sites of BCYRN1 and miR-619-5p. h Luciferase reporter activity of wild-type (WT) or mutated (MUT) BCYRN1 in 293T cells co-transfected with miR-619-5p mimics. i MiR-619-5p was pulled down with biotinylated BCYRN1 in T98G and U251 cells; BCYRN1 was pulled down with biotinylated miR-619-5p in T98G and U251 cells. j Colony formation assays in U251 cells transfected with miR-619-5p mimic alone or co-transfection with BCYRN1. k CCK-8 analysis in U251 cells transfected with miR-619-5p mimic alone or co-transfection with BCYRN1. l Flow cytometry in U251 cells transfected with miR-619-5p mimic alone or co-transfection with BCYRN1. m Transwell assays in U251 cells transfected with miR-619-5p mimic alone or co-transfection with BCYRN1. n Wound-healing assays in U251 cells transfected with miR-619-5p mimic alone or co-transfection with BCYRN1. o Relative expression of (j), (l), (m), (n). Error bars, S.E.M. from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by two-tailed Student’s t test. #P was used to show the significance between NC and Si-BCYRN1-2.

Discussion

Transcriptome profiling is an effective approach for the global view of cancers [36]. More importantly, it is crucial to identify tumor suppressors and oncogenic lncRNAs that elucidate their functions and mechanisms. In this study, we identified hundreds of markedly altered transcripts including 183 lncRNAs through RNA-seq in glioma. Interestingly, altered transcripts were downregulated in glioma compared to controls in our present study as well as other reports [37]. Among them, BCYRN1 was the most significantly downregulated lncRNA in glioma. Gain-of-function and loss-of-function experiments demonstrated that BCYRN1 inhibited the occurrence and development of glioma in vitro and in vivo. BCYRN1 exhibited its function as a ceRNA that competitively bind to miR-619-5p, then regulated target gene CUEDC2 expression and the PTEN/AKT/p21 pathway (Fig. 6f).

LncRNAs are emerging as important regulators in different disease processes including cancer [34, 38–42]. Recently, growing numbers of lncRNAs have been found to be dysregulated in glioma. HOX transcript antisense RNA (HOTAIR) was overexpressed in GBM, crucial to sustain tumor cell proliferation, and regulated by BET bromodomain protein [43]. ECONEXIN is a potential oncogene that regulates TOP2A by sponging miR-411-5p in glioma [23]. In this study, we found that lncRNA BCYRN1 was significantly lower in glioma than normal brain tissues and it was negatively correlated with glioma grade. BCYRN1, termed as BC200, has been found in a variety of cancers as previous studies. Either as an oncogenic lncRNA or a tumor suppressor, BCYRN1 was reported to exert significant biological function in cancers such as NSCLC, ovarian cancer, and gastric cancer [31, 44–48]. However, as a lncRNA derived from brain cytoplasm, the expression and function of BCYRN1 in glioma remain unknown. We believe that it is the first comprehensive characterization of BCYRN1 function and mechanism in glioma. Our results revealed the clinical significance of BCYRN1 and indicated that BCYRN1 might be a candidate in diagnosis and treatment of glioma.

It has been extensively reported that cytoplasmic lncRNAs could function as miRNA sponge to modulate mRNA stability or translation and affect related signaling pathways [49–53]. Bioinformatic analyses and luciferase reporter assays verified that miR-619-5p was the binding target of BCYRN1. MiR-619-5p has been reported to play important roles in several diseases [54, 55]. For example, miR-619-5p was markedly downregulated in colorectal carcinoma and predicted to be a prognostic indicator of CRC patients [55]. However, the regulatory roles of miR-619-5p in glioma remain unclear. In this study, we found that miR-619-5p could promote cell proliferation and migration in glioma and sponged by BCYRN1. Of course, the ceRNA network has its own limitation, and additional studies of lncRNAs as ceRNA in human cancers are needed.

BCYRN1 shared common miR-619-5p binding sites with CUEDC2. CUEDC2 played critical roles in many biological processes, such as cell cycle, inflammation, and tumorigenesis [56–62]. As a multifunctional protein, the
function of CUEDC2 in cancers is debated. Li et al. demonstrated that CUEDC2 acted as a tumor suppressor and inhibited the tumorigenicity of glioma by inactivating STAT3 and NF-κB signaling pathways [35]. While Wang et al. found that CUEDC2 contributed to cisplatin-based chemotherapy resistance by regulating p38 MAPK.
LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2... 6889

signaling and was a promising biomarker and therapeutic target of cisplatin resistance in ovarian serous carcinoma [62]. In this study, we showed that BCYRN1 was downregulated in glioma and the lower expression was more likely to be poor overall survivals, which supported that reduced level of BCYRN1 was correlated with poor prognosis.

Finally, we explored downstream targets of CUEDC2 essential for BCYRN1-mediated tumor suppressor function. Knockdown BCYRN1, as well as overexpression of miR-619-5p, activated AKT signaling, increased expression of P-AKT protein, decreased expression of PTEN and P21 through downregulating CUEDC2. In fact, PTEN/AKT signaling has been widely reported to play an important role in tumors [63–65].

In conclusion, we performed high-throughput RNA sequencing to uncover a downregulated LncRNA BCYRN1 in glioma and verified with clinical glioma samples. BCYRN1 inhibited glioma progression in vitro and in vivo. Our study revealed a mechanism for BCYRN1 that competitively bind miR-619-5p, in turn, suppressed glioma proliferation, migration through inactivating the CUEDC2/PTEN/AKT/p21 pathway. Overall, our study provided a new perspective to identify the potential biomarkers and therapeutic targets for glioma.

Materials and methods

Clinical samples preparation

All fresh glioma patient tumor samples and normal tissues were collected from Department of Neurosurgery of The First Affiliated Hospital of University of Science and Technology of China, which was approved by the Human Research Ethics Committee of the hospital. In this study, we obtained the written informed consent from each patient. A total of 111 resected brain tumors were obtained from May 2015 to May 2019, and all tumor tissues were clinically and histopathological diagnosed as glioma (WHO I/II 46, WHO III/IV 65). Normal brain tissues obtained from 22 patients with brain tissue resection due to craniocerebral injury during the period from May 2015 to May 2019. All samples were rinsed with PBS after operation, and then were cut into small pieces with RNAlater (TransGen) immersed. All samples were stored in −80 °C for the following experiments.

Cell culture

Glioma cell lines U251, T98G, U87, TJ905 and U373 in the experiments were purchased from the ATCC. All cell lines were cultured in DMEM medium (HyClone) containing 10% FBS (Clark Bioscience) and stored in a humidified incubator at 37 °C with 5% CO2.

Plasmids construction and cell transfection

Our plasmids were constructed with restriction-enzyme digestion and ligation or with recombinant methods (Vazyme). Full length of BCYRN1 was inserted into Plko.1 vector and CDS of CUEDC2 was inserted into PEGFP-C1 vector, respectively. SiRNAs, miRNA mimic and inhibitors were purchased from RiboBio. Plasmid and siRNAs transfection were conducted with Lipofectamine 3000 (Invitrogen) according to the manufacturer’s protocol. The sequences are showed in Table S3.
Fig. 6 BCYRN1 inhibits glioma progression through CUEDC2/PTEN/Akt/P21 signaling pathway. a GO analysis and annotation of 44 targeted mRNAs in biological processes. b The protein expression levels of PI3K/Akt signaling related proteins in T98G cells treated with BCYRN1 siRNAs. c The protein expression levels of PI3K/Akt signaling related proteins in T98G cells treated with miR-619-5p mimic. d The protein expression levels of PI3K/Akt signaling related proteins in T98G cells treated with CUEDC2 siRNAs. e The protein expression level of PI3K/Akt signaling related proteins in T98G cells treated with miR-619-5p inhibitor alone or co-transfection with BCYRN1 siRNAs. f Hypothesis diagram illustrates function and mechanism of BCYRN1 in glioma. Error bars, S.E.M. from three independent experiments. ****p < 0.0001 by two-tailed Student’s t test. #P was used to show the significance between NC and Si-BCYRN1-2 or NC and Si-CUEDC2-2.

Funding This study was support by the National Natural Science Foundation of China (No:81902525), Natural Science Foundation of Anhui Province (No: 1908085QH336), USTC Research Funds of the Double First-Class Initiative (No: YD9100002002), the Fundamental Research Funds for the Central Universities (No: WK9110000033) and Special Fund Project for Guiding Local Science and Technology Development by the Central Government (No: 2017070802D144).

Author contributions CSN and SSH designed this project. MLM and WXN performed the experiments. XMZ collected specimen. SSH analyzed the data and wrote the paper. All authors have discussed the results and made comments on the experiment.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166–93.
3. D’Amico RS, Englander ZK, Canoll P, Bruce JN. Extent of resection in glioma—a review of the cutting edge. World Neurosurg. 2017;103:538–49.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
5. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.
6. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.
7. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199–208.
8. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193:651–69.
9. Hu S, Shan G. LncRNAs in stem cells. Stem Cells Int. 2016;2016:2681925.
10. Hu S, Wang X, Shan G. Insertion of an Alu element in a lncRNA leads to primate-specific modulation of alternative splicing. Nucleic Acids Res. 2016:23:1011–9.
11. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nucleic Acids Res. 2015;22:256–64.
12. Shao M, Liu W, Wang Y. Differentially expressed LncRNAs as potential prognostic biomarkers for glioblastoma. Cancer Genet. 2018;226-227:23–29.
13. Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell 2019;179:1033–55.
14. Luo S, Lu JY, Liu L, Yin Y, Chen C, Han X, et al. Divergent lncRNAs regulate gene expression and lineage differentiation in pluripotent cells. Cell Stem Cell. 2016;18:637–52.
15. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 2013;152:1308–23.
16. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 2018;34:142–57.
17. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39:925–38.
18. Dhir A, Dhir S, Proudfoot NJ, Jopling CL. Microprocessor mediates transcriptional termination of long noncoding RNA transcripts hosting microRNAs. Nat Struct Mol Biol. 2015;22:319–27.
19. Jia P, Cai H, Liu X, Chen J, Ma J, Wang P, et al. Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a. Cancer Lett. 2016;381:359–69.
20. Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, et al. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro Oncol. 2013;15:1595–603.
21. Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016;7:13616.
22. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. mi6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell. 2017;31:591–606.e6.
23. Deguchi S, Katsushima K, Hatanaka A, Shinjo K, Ohka F, Wakabayashi T, et al. Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene. 2017;36:4629–40.
24. Han M, Wang S, Fritah S, Wang X, Zhou W, Yang N, et al. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling. Brain. 2020;143:512–30.
25. Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.
26. Huang T, Alvarez AA, Panengi RP, Horbinski CM, Lu S, Kim SH, et al. A regulatory circuit of miR-125b/miR-20b and Wnt...
signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nat Commun. 2016;7:12885.

27. Sun B, Zhao X, Ming J, Liu X, Liu D, Jiang C. Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma. Oncogene. 2019;38:6142–57.

28. Ahir BK, Lakka SS. Elucidating the microRNA-203 specific biological processes in glioblastoma cells from comprehensive RNA-sequencing transcriptome profiling. Cell Signal. 2019;53:22–38.

29. Wu DI, Wang T, Ren C, Liu L, Kong D, Jin X, et al. Down-regulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemo-resistance to carboplatin. Oncol Lett. 2016;11:1189–94.

30. Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, Atti A, et al. Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 2016;7:e2262.

31. Booy EP, McRae EK, Koul A, Lin F, McKenna SA. The long non-coding RNA BCYRN1 is critical for cancer cell survival and proliferation. Mol Cancer. 2017;16:109.

32. Bossi L, Figueroa-Bossi N. Competing endogenous RNAs: a target-centric view of small RNA regulation in bacteria. Nat Rev Microbiol. 2016;14:775–84.

33. Wang R, Zhang S, Chen X, Li N, Li J, Jia R, et al. CircNTSE Acts as a Sponge of miR-422a to Promote Glioblastoma Tumorigenesis. Cancer Res. 2018;78:4812–25.

34. Wu P, Cai J, Chen Q, Han B, Meng X, Li Y, et al. Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019;10:2045.

35. Li F, Tang C, Jin D, Guan L, Wu Y, Liu X, et al. CUEDC2 suppresses glioma tumorigenicity by inhibiting the activation of STAT3 and NF-κB signaling pathway. Int J Oncol. 2017;51:115–27.

36. Casamassimi A, Federico A, Rienzo M, Esposito S, Ciccodicola A. Transcriptome profiling in human diseases: new advances and perspectives. Int J Mol Sci. 2017;18:1652.

37. Balci T, Yilmaz Sulsurer S, Kayabasi C, Ozmen Yelken B, Biray Avci C, Gunduz C. Analysis of dysregulated long non-coding RNA expressions in glioblastoma cells. Gene. 2016;590:120–2.

38. Hua JT, Chen S, He HH. Landscape of noncoding RNA in prostate cancer. Trends Genet. 2019;35:840–51.

39. McDonell P, Guttmann M. Approaches for understanding the mechanisms of long noncoding RNA regulation of gene expression. Cold Spring Harb Perspect Biol. 2019;11:a032151.

40. Liu K, Wang BJ, Han W, Chi CH, Gu C, Wang Y, et al. CFlm25-regulated lncRNA acv3UTR promotes gastric tumorigenesis via miR-590-5p/YAP1 axis. Oncogene. 2020. https://doi.org/10.1038/s41388-020-1213-8.

41. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.

42. Li L, Wu P, Wang Z, Meng X, Zha C, Li Z, et al. NonCONOA: a database of experimentally supported non-coding RNAs and drug targets in cancer. J Hematol Oncol. 2020;13:15.

43. Pastori C, Kapranov P, Penas C, Peschansky V, Volmar CH, Sarkaria JN, et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci USA. 2015;112:8326–31.

44. Hu T, Lu YR. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer. Cancer Cell Int. 2015;15:56.

45. Zhang XY, Zhang LX, Tian CI, Tang XY, Zhao LM, Guo YL, et al. LncRNAs BCYRN1 promoted the proliferation and migration of rat airway smooth muscle cells in asthma via upregulating the expression of transient receptor potential 1. Am J Transl Res. 2016;8:3409–18.

46. Peng J, Hou F, Feng J, Xu SX, Meng XY. Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 in vitro and in vivo. Oncol Lett. 2018;15:5809–18.

47. Zhai H, Li Y. BCYRN1 is correlated with progression and prognosis in gastric cancer. Biosci Rep. 2019;39:BSR20190505.

48. Yu W, Xiang D, Ji H, He X, Sheng J, Long Y, et al. The IncRNA BCYRN1 Functions as an Oncogene in Human Glioma by Downregulating miR-125a-5p in vitro. Cancer Manag Res. 2020;12:1151–61.

49. Hansen TB, Jensen TL, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.

50. Karreth FA, Pandolfo P. ceRNA cross-talk in cancer: when ce- banking rivalries go awry. Cancer Discov. 2013;3:1113–21.

51. Tay Y, Rinn J, Pandolfo P. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–52.

52. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17:272–83.

53. Ge X, Li GY, Jiang L, Jia L, Zhang Z, Li X, et al. Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203-30/SNAI axis. Oncogene. 2019;38:3061–76.

54. Chen G, Gu Y, Han P, Li Z, Zhao JL, Gao MZ. Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619-5p activity and facilitating HDAC3 expression. J Cell Physiol. 2019;234:18686–98.

55. Qiu G, Zhang XB, Zhang SQ, Liu PL, Wu W, Zhang JY, et al. Dysregulation of MALAT1 and miR-619-5p as a prognostic indicator in advanced colorectal cancer. Oncol Lett. 2016;12:5036–42.

56. Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, et al. CUE domain containing 2 regulates degradation of protegerin receptor by ubiquitin-proteasome. EMBO J. 2007;26:1831–42.

57. Chen Y, Wang SX, Mu R, Luo X, Liu ZS, Liang B, et al. Dysregulation of the miR-324-5p-CUEDC2 axis leads to macrophage dysfunction and is associated with colon cancer. Cell Rep. 2014;7:1982–93.

58. Wu QY, Zhu YY, Liu Y, Wei F, Tong XY, Cao J, et al. CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukakemogenesis of acute myeloid leukaemia. Cell Death Dis. 2018;9:774.

59. Li HY, Liu H, Wang CH, Zhang JY, Man JH, Gao YF, et al. Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat Immunol. 2008;9:533–41.

60. Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao Y, et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med. 2011;17:708–14.

61. Thomas C, Gustafsson JAA. CUE hints at tumor resistance. Nat Med. 2011;17:658–60.

62. Wang A, Li J, Zhou T, Li T, Cai H, Shi H, et al. CUEDC2 contributes to cisplatin-based chemotherapy resistance in ovarian serious carcinoma by regulating p38 MAPK signaling. J Cancer. 2019;10:1800–7.

63. Lauria A, Peirone S, Giudice MD, Priante F, Rajan P, Caselle M, et al. Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles. Nucleic Acids Res. 2020;48:1730–47.

64. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol. 2017;45:62–71.

65. Hu L, Li X, Liu Q, Xu J, Ge H, Wang Z, et al. UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multidrug resistance to chemotherapy. Oncogene. 2017;36:1145–56.

66. Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci. 2011;12:495–508.